Grant: Master's Award: Canada Graduate Scholarships
McMaster University
$17,500.00
Pilot Study for First-Ever Randomized Controlled Trial on Epinephrine Auto-Injector Dosages and Needle Lengths in Treating Anaphylaxis
FY 2021-22
Summary
Many individuals have serious allergies to foods, medication, or insects. In some cases, these can cause a severe reaction called anaphylaxis, which can cause symptoms such as breathing difficulty, hives, or sudden blood pressure loss. Anaphylaxis is a life-threatening medical emergency and must be treated immediately.Patients with allergies are prescribed epinephrine auto-injectors (eg EpiPen) that are used as soon as they experience an anaphylactic reaction. They are injected into the thigh muscle, and they release a dose of life-saving epinephrine. However, different people have different-shaped thighs and there is very little evidence on how much epinephrine is enough to save someone. This is alarming to patients with allergies because the injector they carry with them might not save them during an anaphylactic reaction, which is what happened to 15-year-old Natasha Ednan-Laperouse in the UK. Despite using two EpiPens, she suffered a fatal reaction after eating a baguette that contained undeclared sesame seeds, which she was allergic to.Our project is to conduct a high-quality clinical trial to investigate the optimal dose of epinephrine and the optimal needle length for these injectors. The study will begin at the McMaster University Medical Centre and St. Josephs Healthcare Hamilton (Hamilton, Ontario), and if found to be feasible, expanded across Canada in a subsequent larger study. The project will be led by world-renowned doctors and researchers, along with patients who have experienced anaphylaxis, and their families.The results of our study will be the first globally to investigate the optimal dose and needle length in these injectors. Our evidence will inform future research, which will save more patients from suffering fatal anaphylactic reactions.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
467109
Name
Chu Alexandro
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Pilot Study for First-Ever Randomized Controlled Trial on Epinephrine Auto-Injector Dosages and Needle Lengths in Treating Anaphylaxis
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Allergy; Anaphylaxis; Emergency Department; Epinephrine; Evidence-Based Medicine; Health Policy; Immunology; Patient Guidelines; Pilot Study; Randomized Controlled Trial
Abstract
Many individuals have serious allergies to foods, medication, or insects. In some cases, these can cause a severe reaction called anaphylaxis, which can cause symptoms such as breathing difficulty, hives, or sudden blood pressure loss. Anaphylaxis is a life-threatening medical emergency and must be treated immediately.Patients with allergies are prescribed epinephrine auto-injectors (eg EpiPen) that are used as soon as they experience an anaphylactic reaction. They are injected into the thigh muscle, and they release a dose of life-saving epinephrine. However, different people have different-shaped thighs and there is very little evidence on how much epinephrine is enough to save someone. This is alarming to patients with allergies because the injector they carry with them might not save them during an anaphylactic reaction, which is what happened to 15-year-old Natasha Ednan-Laperouse in the UK. Despite using two EpiPens, she suffered a fatal reaction after eating a baguette that contained undeclared sesame seeds, which she was allergic to.Our project is to conduct a high-quality clinical trial to investigate the optimal dose of epinephrine and the optimal needle length for these injectors. The study will begin at the McMaster University Medical Centre and St. Josephs Healthcare Hamilton (Hamilton, Ontario), and if found to be feasible, expanded across Canada in a subsequent larger study. The project will be led by world-renowned doctors and researchers, along with patients who have experienced anaphylaxis, and their families.The results of our study will be the first globally to investigate the optimal dose and needle length in these injectors. Our evidence will inform future research, which will save more patients from suffering fatal anaphylactic reactions.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Chu, Alexandro
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~